Health Economics›Cervical cancer›Persistent recurrent or metastatic disease first-line therapy

Persistent recurrent or metastatic disease first-line therapy

Cervical cancer · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP), Bevacizumab, Pembrolizumab Variant #01	—	R 114 618	21d	—	26.4 mo	36	R 3 964 926 PFS proxy	2
Cisplatin and Paclitaxel (TP), Bevacizumab, Pembrolizumab Variant #01	—	R 113 575	21d	—	26.4 mo	36	R 3 958 664 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #01	—	R 84 794	21d	—	26.4 mo	35	R 2 886 392 PFS proxy	2
Cisplatin and Paclitaxel (TP) and Pembrolizumab Variant #01	—	R 83 588	21d	—	26.4 mo	35	R 2 879 160 PFS proxy	2
ABCP Variant #05	—	R 63 886	21d	13.7 mo	32.1 mo	7	R 444 555 PFS proxy	2
Cisplatin and Paclitaxel (TP), Atezolizumab, Bevacizumab Variant #01	—	R 62 842	21d	13.7 mo	32.1 mo	2	R 125 684 PFS proxy	2
Paclitaxel, Topotecan, Bevacizumab Variant #01	—	R 42 176	21d	—	—	~2	~R 84 353 indirect	—
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 32 363	28d	10.4 mo	19.8 mo	7	R 224 167 PFS proxy	3
Cisplatin and Paclitaxel (TP) and Bevacizumab Variant #01	—	R 31 301	21d	10.4 mo	16.8 mo	2	R 62 602 PFS proxy	4
Topotecan monotherapy Variant #01	—	R 18 138	21d	—	~9.0 mo	~4	~R 72 553 PFS proxy · indirect	2
Cisplatin and Ifosfamide Variant #01	—	R 13 954	21d	~6.0 mo	~48.0 mo	~8	~R 111 628 PFS proxy · indirect	2
Paclitaxel and Topotecan Variant #01	—	R 12 190	21d	—	9.6 mo	2	R 24 380 PFS proxy	—
Cisplatin and Topotecan Variant #01	—	R 11 177	21d	6.0 mo	10.3 mo	6	R 67 063 PFS proxy	1
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	~4.7 mo	~22.3 mo	~6	~R 33 004 PFS proxy · indirect	4
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	10.3 mo	6	R 23 595 PFS proxy	1
Cisplatin and Vinorelbine (CVb) Variant #01	—	R 2 418	21d	—	10.0 mo	6	R 14 510 PFS proxy	1
Cisplatin and Mitomycin Variant #01	—	R 1 656	28d	—	—	~9	~R 14 902 indirect	—
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	—	12.9 mo	7	R 9 204 PFS proxy	5
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	—	17.2 mo	18	R 18 445 PFS proxy	4
Paclitaxel monotherapy Variant #02	—	R 734	28d	~4.7 mo	~13.1 mo	~7	~R 5 141 PFS proxy · indirect	22
Cisplatin monotherapy Variant #01	—	R 588	21d	—	19.5 mo	2	R 1 177 PFS proxy	1
Carboplatin monotherapy Variant #01	—	R 535	21d	~5.8 mo	~21.0 mo	~2	~R 1 070 PFS proxy · indirect	7
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	~9.0 mo	~12	~R 5 490 PFS proxy · indirect	2

24 of 24 regimens shown